# A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy

> **NCT04150575** · PHASE2 · UNKNOWN · sponsor: **Shanghai Henlius Biotech** · enrollment: 21 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** HLX10+Albumin-Bound Paclitaxel

## Key facts

- **NCT ID:** NCT04150575
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-10
- **Primary completion:** 2022-06-15
- **Final completion:** 2022-09-15
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2022-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04150575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04150575, "A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04150575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*